| abstract |
The present invention relates to a bridged ring compound as a hepatitis C inhibitor and a preparation method thereof, and particularly relates to a compound represented by formula (I) or (Ia) or a stereoisomer, tautomer, nitrogen oxide, and hydrate thereof. , Solvates, metabolites, pharmaceutically acceptable salts or prodrugs, and also relates to intermediates for the preparation of compounds represented by formula (I) or (Ia); the present invention also discloses compounds containing formula (I) or (Ia) A pharmaceutical composition of the compound and the use of a compound of formula (I) or (Ia) and a pharmaceutical composition thereof in a medicament for treating HCV infection. |